Gene Therapy for Rare Blindness Shows Unexpected Cross-Eye Benefits

Patients with LHON experience sudden, irreversible vision loss primarily affecting young men, with the condition causing central vision loss in one eye followed by the other.

In a clinical trial designed around the logic of comparison, something unexpected interrupted the experiment: a gene therapy injected into one eye appeared to heal both. GenSight Biologics' Lumevoq, tested in 37 patients with a rare and devastating inherited blindness called LHON, produced vision improvements in 78 percent of patients bilaterally — including in eyes that received only a placebo. The finding, published in December 2020, quietly reframes what scientists thought they understood about the eye's boundaries, and opens a wider door for gene therapy as a discipline still learning the

Gene Therapy for Rare Blindness Shows Unexpected Cross-Eye Benefits

Cobertura Relacionada

Receba o Register no seu e-mail